Submitted by moderna-user-01 on Tue, 02/11/2020 - 10:45
Preclinical development: 
100
Phase 1: 
50
Phase 2: 
0
Phase 3: 
0

Modality:

Program indication: 

Epstein-Barr virus (EBV) vaccine

Moderna rights: 

Worldwide

Preclinical development(sub program): 
65
Phase 1(sub program): 
0
Phase 2(sub program): 
0
Phase 3(sub program): 
0